SCHEDULE: Renaissance Technologies Discloses 5.11% Stake in Generation Bio

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 5.11% beneficial ownership stake in Generation Bio Co. as of July 1, 2025.

Summary

• Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed a Schedule 13G, indicating their beneficial ownership in Generation Bio Co.
• The reporting persons collectively beneficially own 344,263 shares of Generation Bio Co.'s Common Stock.
• This ownership represents 5.11% of the total class of securities.
• The event requiring this filing, which is the crossing of the 5% ownership threshold, occurred on July 1, 2025.
• Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation hold sole voting power and sole dispositive power over all 344,263 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Generation Bio Co.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements about the issuer's operations or financial health.

Future Outlook

NA

Industry Context

This filing reflects a passive institutional investment by Renaissance Technologies in Generation Bio Co., a biotechnology firm. Such disclosures are standard for investment advisers and parent holding companies when their beneficial ownership in a public company exceeds 5%, providing transparency to the market regarding significant equity stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which may be viewed as a signal of confidence in the company by a major fund.
• Company Management: Notifies management of a significant passive investor holding over 5% of the company's common stock.

Key Dates

Keywords

Generation Bio Co., Renaissance Technologies, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Equity Stake